Mavenir Demonstrates Automated Deployment of Cloud-Native 5G Core at MWC LA
21.10.2019 16:00:00 EEST | Business Wire | Press release
Mobile World Congress: Mavenir, a US-based Network Software Provider, and the industry's only end-to-end cloud-native vendor for CSPs, announced today its 5G Core platform, which includes a comprehensive set of 5G core functions on a containerized cloud-native platform. The decomposition of functions into these modular units provides the operators the flexibility to scale them independently; scalability and flexibility that wasn’t possible with 4G EPC.
Mavenir has invested heavily in developing the 5G Core solution from the ground-up on cloud-native principles that can still be retrofitted on EPCs. The solution encompasses all the major 5G core elements, such as AMF, SMF, UPF, NRF, UDSF, PCF, UDM, UDR, NSSF, AUSF, BSF, N3IWF, SCP, SEPP, and SMSF. All these functions are implemented as micro-services in containers. In addition, Mavenir is also building remaining 5G core functions, NEF, 5G-EIR, NWDAF etc.
The Mavenir 5G Core also combines 4G EPC functionality and offers a ‘Converged Mobile Core’ solution that supports both 4G and 5G subscribers. In addition, the Mavenir 5G Core supports all Standalone (SA) and Non-Standalone (NSA) options. This includes 5G SA Option 2 and Option 5, as well as 5G NSA Option 4 and Option 7. With this comprehensive solution, operators will be able to support in parallel existing 4G subscribers, deploy new commercial grade 5G use cases and reap the benefit of a full array of features and capabilities that 5G promises in early 2020.
Mavenir’s investment in building the 5G Core in a future proof way has generated tremendous interest from service providers around the globe. Mavenir’s 5G Core is being tested at Tier-1 operators in Asia Pacific, Europe and in North America.
“Mavenir is engaged with almost all the leading operators in all regions that are showing eagerness in being early adopters and taking advantage of a truly cloud-native microservices-based 5G Core solution,” said Pardeep Kohli, Mavenir’s President and CEO. “This 5G Core allows mobile operators to move directly to next generation technology instead of investing in older 4G elements and Mavenir has the resources and plans to continue to develop the entire scope of 5G Core portfolio.”
Added Kohli, “This 5G Core solution, along with Mavenir’s recent announcement of 4G/5G OpenRAN, affirms the fact that Mavenir is a truly end-to-end network provider.”
At Mobile World Congress Los Angeles, Mavenir will be showcasing the deployment of 6 different 5GC CNFs. Mavenir’s 5G Core solution will be demonstrated along with automation to deploy the Container as a Service (CaaS) and Platform as a Service (PaaS) based on Cloud Native Computing Foundation (CNCF) open source components. To complement the leading edge 5G Core solution, Mavenir has developed automation of deployment and configuration of the CaaS, PaaS and 5G Core Container Network Functions (CNFs).
Request a meeting or learn more here.
About Mavenir:
Mavenir is the industry's only end-to-end, cloud-native network software provider. Focused on accelerating software network transformation and redefining network economics for Communications Service Providers (CSPs) by offering a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN – Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users. Leveraging industry-leading firsts in VoLTE, VoWiFi, Advanced Messaging (RCS), Multi-ID, vEPC, and open RAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 130 countries, which serve over 50% of the world’s subscribers.
We embrace disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation, and revenue protection. Learn more at www.mavenir.com
Mavenir, the M logo, and CloudRange are trademarks owned by Mavenir Systems, Inc.
Copyright © 2019 Mavenir Systems, Inc. All Rights Reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191021005027/en/
Contact information
Maryvonne Tubb
Mavenir PR
NA-Loren Guertin
MatterNow
EMEA-Kevin Taylor
GlobalResultsPR
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom